{
    "medicine_id": "fea63feb553fa40990dcbdfdb9dd414cedc33f57",
    "platform_id": "7070",
    "metadata": {
        "name": "Efavirenz Milpharm 600 mg film coated tablets",
        "composition": "Each film coated tablet contains 600 mg of efavirenz",
        "clinical_particulars": {
            "therapeutic_indications": "Efavirenz is indicated in antiviral combination treatment of human immunodeficiency virus 1 HIV 1 infected adults adolescents and children 3 months of age and older and weighing at least 3 5 kg Efavirenz has not been adequately studied in patients with advanced HIV disease namely in patients with CD4 counts 50 cells mm3 or after failure of protease inhibitor PI containing regimens Although cross resistance of efavirenz with PIs has not been documented there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after failure of regimens containing efavirenz For a summary of clinical and pharmacodynamic information see section 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Patients with severe hepatic impairment Child Pugh Class C see section 5 2 Co administration with terfenadine astemizole cisapride midazolam triazolam pimozide bepridil or ergot alkaloids for example ergotamine dihydroergotamine ergonovine and methylergonovine because competition for CYP3A4 by efavirenz could result in inhibition of metabolism and create the potential for serious and or life threatening adverse reactions for example cardiac arrhythmias prolonged sedation or respiratory depression see section 4 5 Co administration with elbasvir EBR and grazoprevir GZR due to the potential for significant decreases in plasma concentrations of EBR and GZR see section 4 5 Herbal preparations containing St John s wort Hypericum perforatum due to the risk of decreased plasma concentrations and reduced clinical effects of efavirenz see section 4 5 Patients with a family history of sudden death or of congenital prolongation of the QTc interval on electrocardiograms or with any other clinical condition known to prolong the QTc interval a history of symptomatic cardiac arrythmias or with clinically relevant bradycardia or with congestive cardiac failure accompanied by reduced left ventricle ejection fraction severe disturbances of electrolyte balance e g hypokalemia or hypomagnesemia Patients taking drugs that are known to prolong the QTc interval proarrythmic These drugs include antiarrhythmics of classes IA and III neuroleptics antidepressive agents certain antibiotics including some agents of the following classes macrolides fluoroquinolones imidazole and triazole antifungal agents certain non sedating antihistamines terfenadine astemizole cisapride flecainide certain antimalarials methadone",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Cellulose, microcrystalline (Grade -101) (E460);Low-substituted hydroxypropyl cellulose (LH-21);Lactose monohydrate;Hydroxypropyl cellulose (low viscosity grade);Silica, colloidal anhydrous;Crospovidone (type \u2013 B);Sodium lauryl sulphate;Cellulose, microcrystalline (Grade 200) (E460);Crospovidone (type \u2013 A);Magnesium stearate;Hypromellose type 2910 (E464);Macrogol;Titanium dioxide (E171);Iron oxide yellow (E172)",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2022-08-24"
    }
}